ML STRATEGIES, LLC for NOVARTIS PHARMACEUTICALS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S 484, Enhancing Drug Safety and Innovation Act of 2007, Title 1, drug safety; and Title 3, clinical trials registry and results. Federal Food, Drug and Cosmetic Act (21 USC 301), Chapters 1-9 as they relate to the review, approval and regulation of drugs biologics and devices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK BUSE | N/A |
| KENNETH CONNOLLY | STAFF DIRECTOR SENATE EPW COMMITTEE |
| STEVEN IRIZARRY | — |
| DAVID LEITER | N/A |
| PATRICK D MARA | N/A |
| ROBERT NEAL MARTIN | N/A |
| JEREMY RABINOVITZ | CHIEF OF STAFF - CONGRESSWOMAN LOIS CAPPS |
Medicare/Medicaid MMM
* Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK BUSE | N/A |
| KENNETH CONNOLLY | STAFF DIRECTOR SENATE EPW COMMITTEE |
| STEVEN IRIZARRY | — |
| DAVID LEITER | N/A |
| PATRICK D MARA | N/A |
| ROBERT NEAL MARTIN | N/A |
| JEREMY RABINOVITZ | CHIEF OF STAFF - CONGRESSWOMAN LOIS CAPPS |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.